RNXT
RenovoRx Inc (RNXT)
Healthcare • NASDAQ • $0.86-1.87%
- Symbol
- RNXT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.86
- Daily Change
- -1.87%
- Market Cap
- $38.91M
- Trailing P/E
- N/A
- Forward P/E
- -7.20
- 52W High
- $1.45
- 52W Low
- $0.70
- Analyst Target
- $6.88
- Dividend Yield
- N/A
- Beta
- 1.00
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Company websiteResearch RNXT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.